As a specialist in protein/antibody development, AtaGenix is proud to announce its participation in the 115th Annual Meeting of the American Association for Cancer Research (AACR), scheduled for April 5-10, 2024 in San Diego, USA. The AACR Annual Meeting is one of the largest cancer research conferences in the world, attracting nearly 20,000 professionals from around the world.

The 2024 AACR Annual Meeting serves as a premier platform for researchers, healthcare professionals, and cancer advocates to converge and discuss the latest advancements in cancer research. In 2023, the AACR conference registered 21,706 attendees, underscoring its importance and global reach in the fight against cancer.

AtaGenix invites all attendees to visit Booth 652 to explore its comprehensive range of antibody solutions designed to meet the diverse needs of the scientific and medical communities. Highlights of AtaGenix’s exhibition include:

• Innovative Antibody and Protein Solutions: Demonstrating its prowess in antibody and protein technology, AtaGenix will showcase its bespoke one-stop solutions tailored to meet the rigorous demands of both research and clinical applications.
• Supporting Scientific Discovery: AtaGenix's platforms are designed to accelerate the pace of discovery in life sciences, offering robust support for research in diagnostics, antibody drug development, and more.
• Fostering Biomedical Innovation: AtaGenix is eager to engage with partners and colleagues from around the globe to discuss new scientific achievements and foster collaborative efforts aimed at pushing the boundaries of biomedical innovation.

For further details about AtaGenix and its activities at AACR 2024, please visit [https://www.aacr.org/meeting/aacr-annual-meeting-2024/].